Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Mesenchymal Cell Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Morphology
Mesenchymal Cell Neoplasm

Cancer Family

Mesenchymal Cell Neoplasm

CI-CAN-00000027Explore in graph →

Non-malignant413 active trials10 approved drugs208 evidence items

NCIt: C7059

Overview
Statistics
Survival
Genomics12
Variants & evidence208
Drugs20
Trials1848
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (108)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 26–50 of 108 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Dermatofibrosarcoma protuberans COL1A1-PDGFB fusion is identified in virtually all dermatofibrosarcoma protuberans cases when investigated by newly developed multiplex reverse transcription polymerase chain reaction and fluorescence in situ hybridization assays.
· Hum Pathol · 2008 · PMID 17950782 · validated civic_curation pubmed
Prognostic value of CTNNB1 gene mutation in primary sporadic aggressive fibromatosis.
· Ann Surg Oncol · 2015 · PMID 25341748 · validated civic_curation pubmed
A Molecular Study of Pediatric Spindle and Sclerosing Rhabdomyosarcoma: Identification of Novel and Recurrent VGLL2-related Fusions in Infantile Cases.
· Am J Surg Pathol · 2016 · PMID 26501226 · validated civic_curation pubmed
Recurrent MYOD1 mutations in pediatric and adult sclerosing and spindle cell rhabdomyosarcomas: evidence for a common pathogenesis.
· Genes Chromosomes Cancer · 2014 · PMID 24824843 · validated civic_curation pubmed
Clinicopathologic features and molecular spectrum of spindle cell and sclerosing rhabdomyosarcomas in the head and neck region.
· Int J Clin Exp Pathol · 2018 · PMID 31949721 · validated civic_curation pubmed
Recurrent rearrangements of FOS and FOSB define osteoblastoma.
· Nat Commun · 2018 · PMID 29858576 · validated civic_curation pubmed
Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors.

Showing 26–50 of 108 publications

← Previous
1
2
3
4
5
Next →

· Cancer Discov · 2014 · PMID 24436047 · validated civic_curation pubmed

Evolving classification of rhabdomyosarcoma.

· Histopathology · 2022 · PMID 34958505 · validated civic_curation pubmed

Translocation-positive low-grade fibromyxoid sarcoma: clinicopathologic and molecular analysis of a series expanding the morphologic spectrum and suggesting potential relationship to sclerosing epithelioid fibrosarcoma: a study from the French Sarcoma Group.

· Am J Surg Pathol · 2007 · PMID 17721195 · validated civic_curation pubmed

Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG).

· Neuro Oncol · 2022 · PMID 35395680 · validated civic_curation pubmed

Identification of t(17;22)(q22;q13) (COL1A1/PDGFB) in dermatofibrosarcoma protuberans by fluorescence in situ hybridization in paraffin-embedded tissue microarrays.

· Hum Pathol · 2011 · PMID 21111450 · validated civic_curation pubmed

Clinicopathologic and Molecular Genetic Features of Spindle Cell Rhabdomyosarcoma Harboring ZFP64::NCOA2/3 Fusions: A Series of 14 Cases.

· Mod Pathol · 2025 · PMID 41075874 · validated civic_curation pubmed

A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential.

· Lab Invest · 2004 · PMID 15146165 · validated civic_curation pubmed

Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate.

· Clin Cancer Res · 2006 · PMID 16551858 · validated civic_curation pubmed

Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.

· Clin Cancer Res · 2006 · PMID 16638875 · validated civic_curation pubmed

KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size.

· Am J Pathol · 2002 · PMID 12000708 · validated civic_curation pubmed

Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors.

· Cancer Res · 1999 · PMID 10485475 · validated civic_curation pubmed

The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study.

· BMC Cancer · 2012 · PMID 22439647 · validated civic_curation pubmed

Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma.

· J Clin Oncol · 2013 · PMID 23569312 · validated civic_curation pubmed

Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.

· J Clin Oncol · 2008 · PMID 18955458 · validated civic_curation pubmed

Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib: A Phase 2 Clinical Trial.

· JAMA Oncol · 2016 · PMID 27124835 · validated civic_curation pubmed

Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy.

· Ann Oncol · 2016 · PMID 27371698 · validated civic_curation pubmed

The expanding morphological and genetic spectrum of MYOD1-mutant spindle cell/sclerosing rhabdomyosarcomas: a clinicopathological and molecular comparison of mutated and non-mutated cases.

· Histopathology · 2019 · PMID 30604891 · validated civic_curation pubmed

Detection of COL1A1-PDGFB fusion transcripts and PDGFB/PDGFRB mRNA expression in dermatofibrosarcoma protuberans.

· Mod Pathol · 2007 · PMID 17431412 · validated civic_curation pubmed

Molecular detection of the ETV6-NTRK3 gene fusion differentiates congenital fibrosarcoma from other childhood spindle cell tumors.

· Am J Surg Pathol · 2000 · PMID 10895816 · validated civic_curation pubmed